尊龙凯时·「中国区」官方网站

2021-11-09 GP (HK)’s Global Innovative Drug STC3141 Successfully Dosed the First Patient of its Phase Ib Clinical Trial for ARDS In China

2021-10-20 GP (HK)’s Global Innovative Drug Ryaltris Compound Nasal Spray Has Been Granted Phase Three Clinical Trial Approval

2021-10-19 GP (HK) Acquires 80% Equity of Huachen BioTech, Accelerating the Globalization Development of Amino Acid Industry

2021-08-11 GP (HK) Announces 2021 Interim Results

2021-08-06 GP (HK) Enters into Strategic Cooperation with CoRISMA on Equity Interests and Products, Introducing a Global Innovative Advanced Heart Failure Therapeutic System

2021-08-02 GP (HK) Enters into Investment and Strategic Cooperation Agreements with FastWave

2021-07-27 GP (HK) Announces the Positive Profit Alert, The Consolidated Net Profit Attributable to Owners of the Company for the First Half of 2021 is Expected to Increase Not Less Than 50%

2021-07-08 P (HK)’s Associate OncoSec Enters into A Collaboration Agreement with Merck to Conduct a Global Phase III Study in Advanced Metastatic Melanoma.

2021-07-08 GP(HK) Global Innovative RDC TLX250-CDX Dosed the First Patient with the Expanding Indication in Australia

2021-07-02 GP (HK) Subscribes for New Shares of Sirtex HoldCo and Reaches the TRS Agreements with Natixis.

2021-06-04 GP (HK)’s Two Global Innovative RDC Products Usher in a New Breakthrough, TLX591-CDx Dosed the First Patient in Japan;

2021-06-03 GP (HK) Obtains Exclusive Development and Commercialization Rights of Improved New Drug for Anti-inflammatory and Pain Relief after Ophthalmology Surgery